US Pharma Imports Par Naya Hungama, India Chill?
Arey yaar, suno! US ne apne pharma imports pe naye rules laaye hain, lekin lagta hai India ko zyada farak nahi padega. Kyun? Kyunki yeh naye rules mainly opioid-based medicines ke liye hain, aur India mostly generic medicines export karta hai. Pharmaceuticals Export Promotion Council of India (Pharmexcil) ke chairman, Namit Joshi ne NDTV Profit ko bataya ki yeh initial views hain, aur unki team abhi puri detail check kar rahi hai.
India Ka Pharma Export: Badi Baat!
India US ko kareeb $9 billion ka pharma export karta hai, jo ki US mein use hone wale generic drugs ka 40% hai. Socho, kitna bada business hai!
Trump Sarkar Ka Naya Plan
US President Donald Trump ne Tuesday ko ‘Section 232 investigation’ shuru kar di hai, kyunki US foreign drug manufacturing pe kaafi dependent hai. Iske alawa, Indian pharma companies ne Drug Controller General of India (DCGI) se request ki hai ki No Objection Certificate (NOC) ke naye rules ko thoda relax karein, kyunki isse exports mein dikkat aa rahi hai.
NOC Mein Kya Jhamela Hai?
7 March ko, DCGI ne NOC ke rules badal diye. Ab companies ko pehle importing country se approval leni hogi, uske baad hi woh DCGI se NOC ke liye apply kar sakte hain. Companies chahti hain ki yeh rule thoda aasan ho, taaki exports par effect na pade.
Aage Kya Hoga?
Abhi dekhna hoga ki US ke is kadam ka India ke pharma export par kitna asar padta hai. Lekin experts ka kehna hai ki zyada tension lene ki zarurat nahi hai.
